Anebulo Pharmaceuticals
phase part adaptive study design | Anebulo Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
29 of 53
Related slides by other companies
Compass Therapeutics
Investor Presentation
February 2023
phase study design | Compass Therapeutics
Aeglea BioTherapeutics
Investor Presentation
May 2023
phase clinical trial design | Aeglea BioTherapeutics
ATAI
Investor Presentation
January 2024
trial status first patient dosed in topline data anticipated mid clinical design phase study | ATAI
Checkmate Pharmaceuticals
IPO
August 2020
phase study design | Checkmate Pharmaceuticals
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights